Devyser Diagnostics AB
Research Devyser Diagnostics AB (DVYSR) on Bullrun: market cap SEK 1.01B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDVYSR
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Market capSEK 1.01B
- Financial periodQ2 2026
- RevenueSEK 60.20M
- Net incomeSEK 1.60M
- Free cash flow-SEK 2.10M
- Gross margin76.1%
Valuation Snapshot
latest market cap is SEK 1.01B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 250.60M | -SEK 8.40M | n/a | 80.6% | n/a | SEK 77.50M | SEK 51.90M | SEK 354.40M |
| FY2024 | SEK 216.80M | -SEK 61.50M | n/a | 79.7% | n/a | SEK 144.50M | SEK 59.10M | SEK 349.10M |
| FY2023 | SEK 169.30M | -SEK 53.60M | n/a | 85.5% | n/a | SEK 262.90M | n/a | n/a |
| FY2022 | SEK 126.70M | -SEK 45.90M | n/a | 81.6% | n/a | SEK 363.60M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 1.01B | n/a | n/a | n/a |
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Devyser Diagnostics AB's market cap?
Devyser Diagnostics AB's market capitalization is SEK 1.01B.
What does Devyser Diagnostics AB do?
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results.